EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation

Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma

(2012) Yongping Yang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

(2011) Julien Edeline et al.   CANCER

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models

(2011) Ju Hyun Shim et al.   RADIOLOGY

Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma

(2010) Ahsun Riaz   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma

(2010) Lin Zhou et al.   JOURNAL OF GASTROENTEROLOGY

Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies

(2010) Gianpiero Gravante et al.   LIVER INTERNATIONAL

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma

(2010) H.W. Chen et al.   International Journal of Surgery